Literature DB >> 24691823

Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide.

Jan M Keppel Hesselink1, David J Kopsky, Nancy L Sajben.   

Abstract

BACKGROUND: The prevalence of idiopathic vulvodynia and proctodynia is high. Pain management with anti-depressants and anti-epileptics may induce undesirable side effects. Therefore, topical baclofen cream and palmitoylethanolamide might be new therapeutic options. CASE: A 33-year-old woman with intractable chronic vulvar and anal pain had to abstain from sexual intercourse and could neither cycle nor sit for more than 5 min. The patient did not respond to standard treatments. We prescribed a combination of topical baclofen 5 % and palmitoylethanolamide 400 mg, three times daily. After 3 months her symptoms decreased more than 50 % and sexual intercourse was possible again without pain.
CONCLUSION: Topical baclofen and palmitoylethanolamide can be a viable treatment option in chronic vulvodynia and proctodynia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691823     DOI: 10.1007/s00404-014-3218-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  13 in total

1.  Early experience with topical meloxicam and lidocaine combination for the treatment of vulvodynia.

Authors:  Rufina Kim; Kerri-Lynn Kelly; Merle Olson; J Curtis Nickel
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

2.  Effect of Topical Baclofen 5% on Post-Hemorrhoidectomy Pain: Randomized Double Blind Placebo-Controlled Clinical Trial.

Authors:  Shahram Ala; Mina Alvandipour; Majid Saeedi; Mohaddeseh Mansourifar; Mahila Monajati; Afshin Shiva
Journal:  J Gastrointest Surg       Date:  2019-02-19       Impact factor: 3.452

3.  THE INFLUENCE OF ENDOCANNABINOID SYSTEM ON WOMEN REPRODUCTION.

Authors:  D M Popescu-Spineni; L Guja; C M Cristache; M E Pop-Tudose; A M Munteanu
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Apr-Jun       Impact factor: 1.104

Review 4.  A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation.

Authors:  M L Falsetta; D C Foster; A D Bonham; R P Phipps
Journal:  BJOG       Date:  2016-06-17       Impact factor: 6.531

Review 5.  Endocannabinoid signaling at the periphery: 50 years after THC.

Authors:  Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer
Journal:  Trends Pharmacol Sci       Date:  2015-03-18       Impact factor: 14.819

Review 6.  Skin matters! The role of keratinocytes in nociception: a rational argument for the development of topical analgesics.

Authors:  Jan M Keppel Hesselink; David J Kopsky; Arun K Bhaskar
Journal:  J Pain Res       Date:  2016-12-16       Impact factor: 3.133

7.  Topical phenytoin for the treatment of neuropathic pain.

Authors:  David J Kopsky; Jan M Keppel Hesselink
Journal:  J Pain Res       Date:  2017-02-27       Impact factor: 3.133

Review 8.  Topical Treatments for Localized Neuropathic Pain.

Authors:  Roberto Casale; Z Symeonidou; M Bartolo
Journal:  Curr Pain Headache Rep       Date:  2017-03

9.  New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells.

Authors:  J M Keppel Hesselink; D J Kopsky; N Sajben
Journal:  J Pain Res       Date:  2016-10-03       Impact factor: 3.133

10.  Novel Treatment of Radicular Pain With a Multi-Mechanistic Combination Topical Agent: A Case Series and Literature Review.

Authors:  Pegah Safaeian; Ryan Mattie; Matthew Hahn; Christopher T Plastaras; Zachary L McCormick
Journal:  Anesth Pain Med       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.